Processa Pharmaceuticals Inc expected to post a loss of 12 cents a share - Earnings Preview

Processa Pharmaceuticals

08/08/2025 21:11

Processa Pharmaceuticals Inc PCSA.OQ PCSA.O is expected to  report results on October 28 (estimated) for the period ending September 30 2025

​LSEG's mean analyst estimate for Processa Pharmaceuticals Inc is for a loss of 12 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 64.6% in the last three months. ​

Wall Street's median 12-month price target for Processa Pharmaceuticals Inc is $2.00, about 88.4% above its last closing price of $0.23

This summary was machine generated August 8 at 20:11 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)